Articles |
From the Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.
Correspondence to Balz Frei, PhD, Linus Pauling Institute, Oregon State University, 571 Wenger Hall, Corvallis, OR 97331. E-mail balz.frei.{at}orst.edu
| Abstract |
|---|
|
|
|---|
Key Words: modified LDL metal ions ascorbate atherosclerosis human endothelial cells
| Introduction |
|---|
|
|
|---|
As an important corollary of the "oxidative modification hypothesis of atherosclerosis," antioxidants that can inhibit LDL oxidation may slow the progression of atherosclerosis. Our previous studies have demonstrated that vitamin C (ascorbate) is the most effective water-soluble antioxidant in inhibiting lipid peroxidation in human plasma and also very effectively protects isolated LDL against oxidative modification.14 15 16 17 We and others have shown that physiological concentrations of ascorbate effectively inhibit LDL oxidation under many different oxidizing conditions, including vascular cells in culture (rabbit aortic ECs, human monocytederived macrophages, and murine macrophages), stimulated human neutrophils, myeloperoxidase-derived hypochlorous acid or tyrosyl radicals, aqueous peroxyl radicals, Cu2+, and heme iron.18
However, it is not known whether vitamin C can inhibit atherogenic
modification of LDL by human vascular ECs. Furthermore, while much is
known about the inhibition of LDL oxidation by LDL-associated
antioxidants (eg,
-tocopherol) or extracellular
water-soluble antioxidants (eg, ascorbate),6 13 18 little
is known about the effects of these antioxidants at the cellular level.
Specifically, intracellular antioxidants may play an important role in
limiting a cell's capacity to oxidize LDL. In support of this
hypothesis, enrichment with ß-carotene or
-tocopherol
of cocultured human aortic ECs and SMCs, but not of LDL, has been shown
to result in decreased LDL modification by these cells and consequent
decreased monocyte adhesion.19 20 Similarly,
Parthasarathy21 reported that loading of ECs or
macrophages with a water-soluble derivative of probucol
markedly decreased LDL oxidation by these cells.
Interestingly, nothing is known about the role of intracellular ascorbate in cell-mediated LDL modification. Effects of ascorbate at the cellular level may be of major importance, as cells can accumulate large amounts of ascorbate against a concentration gradient and physiological concentrations of ascorbate in cells are usually considerably higher (in the low millimoles per liter range) than those in extracellular fluids (30 to 150 µmol/L).15 22 23 Therefore, in the present study we investigated atherogenic modification of LDL by human vascular ECs and the role of both extracellular and intracellular vitamin C in this process.
| Methods |
|---|
|
|
|---|
BAECs were obtained from segments of bovine aorta from freshly slaughtered animals at a local meat-processing plant. Aortas were immediately immersed in cold, sterile HBSS containing 100 U/mL penicillin, 100 U/mL streptomycin, and 1.25 µg/mL amphotericin B in a sterile stainless steel container and transported to the laboratory at 4°C. After being rinsed in cold HBSS, one end of the vessel was clamped, the vessel filled with 0.1% collagenase in HBSS and clamped at the other end. The vessels were placed in HBSS and incubated at 37°C for 2 hours, after which the contents were decanted into a sterile 50-mL centrifuge tube. The tube was centrifuged at 800 rpm at 4°C for 5 minutes, and the resulting pellet was resuspended in DMEM containing 15% FBS. Cells were seeded in T-75 flasks, grown in M199 containing 10% FBS, supplemented as described above until they reached confluence, and then split into six-well plates. Cells in culture medium were maintained at 37°C under humidified 5% CO2 in room air, and the medium was changed every 2 days. When the cells reached confluence, the FBS content of the medium was reduced to 5% and the cells were maintained for another 24 hours under these conditions before experiments were initiated.
Isolation of LDL
LDL (1.019 to 1.063 g/mL) was isolated from the plasma of
a healthy, normolipidemic (<160 mg LDL cholesterol per
deciliter) male volunteer by single vertical discontinuous density
gradient ultracentrifugation.16 24
Heparinized blood was collected and centrifuged for 15 minutes
at 2000 rpm. The density of the plasma was adjusted to 1.21 g/mL
by the addition of solid KBr (0.365 g/mL). Centrifuge
tubes were loaded by layering 1.5 mL of density-adjusted plasma under
3.5 mL of 0.154 mol/L NaCl, placed in a near-vertical tube-90
rotor, and centrifuged in a Beckman L7-80M
ultracentrifuge at 70 000 rpm and 7°C for 45 minutes with
slow acceleration and deceleration modes. The yellow LDL band located
in the upper middle portion of the tube was collected into a syringe by
puncturing the tube. Residual KBr and plasma-derived
small-molecular-weight contaminants present in the LDL preparation
were removed by passage through a Sephadex G25M PD-10 column
(Pharmacia) equilibrated with medium. LDL protein was determined by a
modified Lowry assay25 using BSA as the standard. LDL
isolated in this manner is free of detectable amounts of lipid
hydroperoxides (<0.005 molecule of lipid hydroperoxides per LDL
particle)26 and contains <3% albumin
contamination as assessed by both SDSpolyacrylamide gel
electrophoresis and size-exclusion HPLC.27 Isolated LDL
was used for experiments immediately after preparation.
Experiments
Confluent HAECs, HSECs, or BAECs in six-well plates were washed
twice with HBSS; serum-free Ham's F-10 medium, LDL (0.1 mg protein per
milliliter), and the indicated concentrations of vitamin C were added.
Vitamin C was added from a freshly prepared 5 mmol/L stock
solution of L-ascorbic acid (Sigma) in Ham's F-10 medium.
After incubation for various periods of time (0 to 48 hours),
modification of LDL was assessed as described below.
To determine the cellular uptake and intracellular concentration of vitamin C, confluent ECs were incubated in M199 containing 6% FBS and various concentrations of vitamin C (added from a fresh 5 mmol/L stock solution in M199). After 0 to 24 hours of incubation, the supernatant was removed and the cell monolayer washed twice with HBSS. Cells were trypsinized (0.05% trypsin), collected into HBSS containing 1 mmol/L EDTA, and spun for 5 minutes at 800 rpm and 4°C. The supernatant was discarded and the cell pellet resuspended in 300 µL of HBSS containing 1 mmol/L EDTA. A 200-µL aliquot of this cell suspension was used for ascorbate determination as described below, and a 50-µL aliquot was used for protein determination.25
To examine the role of intracellular ascorbate in EC-mediated LDL modification, cells were incubated for 16 hours in M199 containing 6% FBS and the indicated concentrations of vitamin C. The cells were then washed twice with HBSS, and serum-free Ham's F-10 medium containing LDL (0.1 mg protein per milliliter) was added. After incubation for various periods of time (0 to 48 hours), modification of LDL was assessed as described below.
Assessment of LDL Modification
Modification of LDL was assessed by agarose gel electrophoresis.
LDL was electrophoresed at 100 V for 30 minutes on a 0.5% agarose gel
(Lipo gels, Beckman) using 0.05 mol/L barbital buffer, pH 8.6.
Gels were fixed, stained, and destained according to the
manufacturer's instructions. Anodic electrophoretic mobility of
modified LDL was expressed as mobility relative to native LDL, which
was defined as 1.0. Increased anodic electrophoretic mobility of LDL
has been previously shown to correlate with increased recognition of
LDL by the scavenger receptors on macrophages, resulting in
formation of lipid-laden foam cells characteristic of the early
atherosclerotic fatty streak.4 13
Quantification of Ascorbate
Ascorbate was measured by HPLC with electrochemical
detection.15 16 In brief, the sample was mixed with an
equal volume of cold 5% (wt/vol) metaphosphoric acid containing 1
mmol/L of the metal ion chelator diethylenetriaminepentaacetic
acid (Sigma) and centrifuged to remove the precipitated
proteins. An aliquot of the supernatant was chromatographed on
an LC8 column (150x4.6 mm inner diameter, 3-µm particle size;
Supelco) using 99% deionized water and 1% methanol containing 40
mmol/L sodium acetate and 1.5 mmol/L
dodecyltriethylammonium phosphate (Q12 ion-pair cocktail,
Regis) as the mobile phase. Ascorbate was detected at an applied
potential of +0.6 V by an LC 4B amperometric electrochemical detector
(Bioanalytical Systems). Ascorbate eluted as a single peak with a
retention time of 5.5 minutes.
Quantification of Intracellular H2O2
Concentrations of H2O2 in HAECs were
measured using 2',7'-diacetyldichlorofluorescin (Polysciences Inc.), a
fluorescent probe that diffuses across cell membranes and is
enzymatically deacetylated by cellular esterases to the more
hydrophilic nonfluorescent reduced dye
2',7'-dichlorofluorescin.28 Intracellular
H2O2 rapidly oxidizes 2',7'-dichlorofluorescin
to the fluorescent metabolite
2',7'-dichlorofluorescein. Cultured HAECs in 96-well plates
were washed with HBSS and then with 100 µL of the assay solution
containing 10 mmol/L 2',7'-diacetyldichlorofluorescin,
1 mmol/L HEPES in HBSS without phenol red was then added.
After incubation for 30 minutes, the fluorescence intensity was
measured in a Citofluor II (Per Septive Biosystems) at an excitation
wavelength of 485 nm and an emission wavelength of 530
nm.28
| Results |
|---|
|
|
|---|
|
LDL incubated in Ham's F-10 medium in the absence of cells (cell-free
control) also became modified in a time-dependent manner, albeit at a
lower rate than in the presence of cells (Fig 1B
). In contrast, LDL
incubated in M199 for up to 48 hours in the presence or absence of
HAECs did not become modified to a detectable degree (relative
electrophoretic mobility=1.0; data not shown). Ham's F-10 medium
contains 1.7 to 3.9 µmol/L iron and
0.2 to 0.6
µmol/L copper,10 30 whereas M199 is free of
detectable amounts of transition metal ions (
0.2
µmol/L).10 These data, therefore, suggest that
HAEC-mediated and cell-free LDL modifications are metal ion dependent,
as has been reported previously for rabbit aortic ECs5 11
and cell-free systems.4 5 10
HAEC-mediated (Fig 1A
) and cell-free (Fig 1B
) LDL modifications in
Ham's F-10 medium were time- and dose-dependently inhibited by
ascorbate, with no detectable LDL modification occurring in the
presence of 260 µmol/L ascorbate for up to 24 and 48
hours of incubation, respectively, in the presence or absence of HAECs.
Interestingly, 65 µmol/L ascorbate exerted an antioxidant
effect during the initial 6 hours of incubation of LDL in the cell-free
system but a slight pro-oxidant effect during longer incubation times
(Fig 1B
). In agreement with this observation, we found that after 24
hours LDL incubation in the cell-free system,
120
µmol/L ascorbate increased LDL modification by up to 60%,
whereas
130 µmol/L ascorbate strongly inhibited or
completely prevented LDL modification (Table 1
).
|
To investigate the role of intracellular vitamin C in LDL modification
by HAECs, we first studied the uptake of the vitamin by these cells. As
shown in Fig 2
, the HAECs used in our
experiments, which were primary cells of the fourth to seventh passage
cultured under conventional conditions, contained very little
endogenous ascorbate (0.4±0.1 nmol/mg protein, n=3
cell preparations). This nonphysiological state
most likely resulted from the subphysiological
concentration of ascorbate in M199, which we measured to be 0.3 to
3.0 µmol/L. Incubation of HAECs in M199 containing 6%
FBS and 100 µmol/L ascorbate led to a time-dependent
accumulation of ascorbate by the cells (Fig 2A
). Intracellular
ascorbate reached a maximal level of 9.5±1.6 nmol/mg protein
(n=3) after 16 hours of incubation. Cellular accumulation of ascorbate
was dependent on the extracellular concentration and was nonsaturable
up to 250 µmol/L (Fig 2B
).
|
HAECs loaded with ascorbate, as described above, oxidized LDL (0.1 mg
protein per milliliter) less extensively than did nonascorbate-loaded
control cells. As shown in Fig 3
, when
LDL was incubated for 18 hours in Ham's F-10 medium with HAECs loaded
previously with 65, 130, or 260 µmol/L ascorbate, the
degree of LDL modification was dose-dependently decreased compared with
control LDL. These results were confirmed in a second experiment in
which preincubation of HAECs with 0, 130, or 260 µmol/L
ascorbate and subsequent incubation for 18 hours with LDL resulted in
its relative electrophoretic mobility of 2.7, 2.0, and 1.8,
respectively. To assess whether intracellular ascorbate was released
from the cells during incubation with LDL, we collected media from the
experiments shown in Fig 3
but did not detect ascorbate (<0.1
µmol/L) in any of these samples.
|
To assess the possibility that the decreased capacity of
ascorbate-loaded HAECs to modify LDL is due to decreased
production of reactive oxygen species by these cells, we
measured intracellular concentrations of H2O2.
As shown in Fig 4
, H2O2 levels were significantly lower (P<.001)
in HAECs loaded with 120 µmol/L ascorbate compared with
nonascorbate-loaded control cells.
|
In addition to HAECs, we used HSECs and BAECs to investigate the role
of intracellular and extracellular vitamin C in EC-mediated LDL
modification. LDL incubated with confluent HSECs in Ham's F-10 medium
became modified in a time-dependent manner (Fig 5
, A and B). In contrast, LDL incubated
with HSECs in M199 for 24 hours did not become modified to a measurable
degree (Fig 5A
); however, after 48 hours of incubation, a slight
increase in the electrophoretic mobility was observed (Fig 5B
).
Coincubation with ascorbate strongly inhibited HSEC-mediated LDL
modi- fication in Ham's F-10 medium in a time- and
concentration-dependent manner (Fig 5
, A and B). Although the
inhibitory effects of added ascorbate appear somewhat
greater than those observed in the presence of HAECs (Fig 1A
), it
should be noted that LDL was modified at a lower rate in the
experiments using HSECs. Thus, the relative electrophoretic mobility of
LDL after 24 hours of incubation with HAECs or HSECs was 5.5 and 3.3,
respectively (cf Figs 1A
and 5A
). Correspondingly, intracellular
ascorbate also appeared more effective at inhibiting LDL modification
by HSECs than HAECs. LDL modification by HSECs preincubated with
60, 180, or 360 µmol/L ascorbate was decreased
dose-dependently compared with LDL modification by
nonascorbate-loaded control cells (Fig 5A
). After 48 hours of
incubation, these inhibitory effects of intracellular
vitamin C were no longer observed (Fig 5B
).
|
In contrast to human ECs, BAECs could not be loaded with vitamin C
(data not shown). Therefore, preincubation of BAECs with ascorbate had
no effect on the subsequent modification of LDL by these cells in
Ham's F-10 medium (data not shown). However, extracellular vitamin C
inhibited BAEC-mediated LDL modification in a concentration-dependent
manner, with
170 µmol/L ascorbate providing complete
protection for 24 hours of incubation (Table 2
).
|
| Discussion |
|---|
|
|
|---|
Most previous investigations of LDL modification by
ECs5 11 12 32 have used a cell line of rabbit aortic
ECs33 and have shown that these cells oxidatively modify
LDL by a mechanism dependent on both transition metal
ions5 11 and thiol compounds released from the
cells.12 It has been suggested that metal ions cause
oxidation of thiols in the medium to thiyl radicals, which may initiate
lipid peroxidation in LDL, either directly or indirectly via
production of reactive oxygen species.12
Interestingly, previous studies of LDL oxidation by human ECs have all
used M199,19 34 35 36 which does not contain detectable
amounts of transition metal ions.10 These studies have
shown very modest LDL modification, usually a relative electrophoretic
mobility of about 1.4 to 1.7,34 36 and sometimes no
detectable modification at all.19 36 We were unable to
detect LDL modification by HAECs in M199, in contrast to metal
ioncontaining Ham's F-10 medium. However, we did observe a relative
electrophoretic mobility of
1.5 for LDL incubated with HSECs in M199
(Fig 5B
). Thus, our data are in line with those of
others,34 36 and at the same time show that significant
LDL modification by human ECs requires metal ions.
The inhibition of EC-mediated LDL oxidation by antioxidants has not
been widely studied.5 11 36 Addition of the lipid-soluble
antioxidant
-tocopherol to incubations with ECs was
shown to inhibit LDL oxidation.5 36 However, in those
experiments,
-tocopherol was added at concentrations
corresponding to 1000 and 2300 nmol/mg LDL
protein,5 36 which is two orders of magnitude higher than
the physiological range of 8 to 24 nmol/mg
protein.37 In contrast, addition of
supraphysiological levels of ß-carotene (200
nmol/mg protein, compared with physiological
levels of
0.5 nmol/mg protein13 ) had no
inhibitory effect on EC-mediated LDL
oxidation.36 The only experiment that assessed the effect
of vitamin C on EC-mediated LDL modification used the rabbit aortic EC
line mentioned above33 and showed that LDL modification
was strongly inhibited by 50 µmol/L
ascorbate.11 The data presented here demonstrate
that physiological concentrations of ascorbate
strongly inhibit LDL modification by human ECs in a concentration- and
time-dependent manner. These findings extend our previous observations
of very strong protective effects of endogenous ascorbate
against lipid peroxidation in human plasma14 15 and
exogenous ascorbate against LDL oxidation by
Cu2+16 17 or activated human
neutrophils.27 Other researchers have shown equally potent
effects of ascorbate against LDL modification by human
monocytederived macrophages.38 Because vitamin C
is present in human plasma,15 22 23
interstitial fluid,23 and arterial
walls39 at concentrations comparable to those used in the
present study, our data strongly suggest that vitamin C can prevent
vascular cellmediated LDL modification in vivo.
Our findings that HAEC-mediated LDL modification is metal ion dependent
and strongly inhibited by vitamin C are remarkable, given the known
pro-oxidant effect of vitamin C in vitro in the presence of transition
metal ions.40 41 We had also observed strong protective
rather than exacerbating effects of ascorbate on LDL oxidation by
Cu2+ or heme iron.16 17 The mechanism by which
extracellular vitamin C protects against metal iondependent LDL
oxidation likely involves inhibition of initiation of lipid
peroxidation16 17 due to decreased
Cu2+-binding to LDL (K. Retsky et al, unpublished
observations) and destruction of lipid hydroperoxides in
LDL17 and possibly, reduction of the transition metal ions
to the fully reduced state.42 It has been suggested that
the simultaneous presence of reduced and oxidized forms of
iron is required for initiation of lipid peroxidation and that no lipid
peroxidation occurs when the metal ion is either completely reduced or
completely oxidized.42 43 Therefore, our observation that
low concentrations of ascorbate exert a pro-oxidant effect on cell-free
LDL modification in Ham's F-10 medium (Table 1
) may be explained by
the partial reduction of transition metal ions in this medium. In
contrast, high concentrations of ascorbate may completely reduce these
metal ions, thus preventing LDL modification (Table 1
). Interestingly,
ascorbate exerted only antioxidant and no pro-oxidant effects when LDL
was incubated with ECs (Figs 1A
and 4
and Table 2
).
A further novel finding of the present study is the reduced
capacity of vitamin Cenriched human ECs to modify LDL. Only a few
previous studies have investigated the role of cell-associated
antioxidants in LDL modification, as opposed to LDL-associated or
extracellular antioxidants. These studies have shown that cultured
vascular cells enriched with
-tocopherol, ß-carotene,
or a water-soluble probucol derivative exhibit a lowered capacity to
modify LDL.19 20 21 The present study shows that human
ECs take up vitamin C from the extracellular fluid and as a consequence
exhibit a lowered capacity to modify LDL. The amounts of intracellular
ascorbate accumulated by HAECs were comparable to those previously
measured in human umbilical vein ECs.31 If one assumes an
intracellular volume of
1 µL/106 HAECs and a protein
content of 0.4 mg/106 cells (A.M. and B.F.,
unpublished observations), then the concentrations of intracellular
ascorbate in HAECs (Fig 2B
) were in the range of 3 to 8
mmol/L, comparable to the levels in human neutrophils,
monocytes, and lymphocytes.22 44 45
The effects of intracellular vitamin C on EC-mediated LDL modification
were not as strong as those of extracellular vitamin C. However, it
should be kept in mind that in vivo intracellular ascorbate levels are
constantly replenished, in contrast to the in vitro experiments
presented here. Although we cannot completely exclude the
possibility that the effects of intracellular ascorbate on LDL
modification were mediated by ascorbate that was released into the
medium, we were unable to detect extracellular ascorbate during
incubations of LDL with ascorbate-enriched ECs. It is possible that
intracellular vitamin C acted by lowering the production rate
of reactive oxygen species by these cells (see Fig 4
), thus lowering
their capacity to modify LDL. Further studies will be required to
clarify the mechanisms by which intracellular ascorbate and other
cellular antioxidants lower the capacity of vascular cells to
oxidatively modify LDL, thereby potentially slowing the initiation and
progression of atherosclerosis.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received July 22, 1996; accepted November 25, 1996.
| References |
|---|
|
|
|---|
2.
Goldstein JL, Ho YK, Basu SK, Brown MS. Binding
site on macrophages that mediates uptake and degradation of
acetylated low density lipoprotein, producing massive
cholesterol deposition. Proc Natl Acad Sci
U S A.. 1979;76:333-337.
3.
Henriksen T, Mahoney EM, Steinberg D. Enhanced
macrophage degradation of low density lipoprotein previously
incubated with cultured endothelial cells: recognition
by receptors for acetylated low density lipoproteins.
Proc Natl Acad Sci U S A.. 1981;78:6499-6503.
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med.. 1989;320:915-924.[Medline] [Order article via Infotrieve]
5.
Steinbrecher UP, Parthasarathy S, Leake DS, Witztum
JL, Steinberg D. Modification of low density lipoprotein by
endothelial cells involves lipid peroxidation and
degradation of low density lipoprotein phospholipids.
Proc Natl Acad Sci U S A.. 1984;81:3883-3887.
6. Keaney JF Jr, Frei B. Antioxidant protection of low density lipoprotein and its role in the prevention of atherosclerotic vascular disease. In: Frei B, ed. Natural Antioxidants in Human Health and Disease. San Diego, Calif: Academic Press; 1994:303-351.
7. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med.. 1996;20:707-727.[Medline] [Order article via Infotrieve]
8. Weis JR, Pitas RE, Wilson BD, Rodgers GM. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J.. 1991;5:2459-2465.[Abstract]
9.
Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G,
Lafont H, Juhan-Vague I. Stimulating effect of oxidized low
density lipoproteins on plasminogen activator
inhibitor-1 synthesis by endothelial
cells. Arterioscler Thromb.. 1991;11:1821-1829.
10. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest.. 1984;74:1890-1894.
11. Steinbrecher UP. Role of superoxide in endothelial-cell modification of low-density lipoproteins. Biochim Biophys Acta.. 1988;959:20-30.[Medline] [Order article via Infotrieve]
12. Sparrow CP, Olszewski J. Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. J Lipid Res.. 1993;34:1219-1228.[Abstract]
13. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med.. 1992;13:341-390.[Medline] [Order article via Infotrieve]
14.
Frei B, Stocker R, Ames BN. Antioxidant defenses
and lipid peroxidation in human blood plasma. Proc Natl
Acad Sci U S A.. 1988;85:9748-9752.
15.
Frei B, England L, Ames BN. Ascorbate is an
outstanding antioxidant in human blood plasma. Proc Natl
Acad Sci U S A.. 1989;86:6377-6381.
16.
Retsky KL, Freeman MW, Frei B. Ascorbic acid
oxidation product(s) protect human low density lipoprotein against
atherogenic modification: anti- rather than prooxidant activity of
vitamin C in the presence of transition metal ions.
J Biol Chem.. 1993;268:1304-1309.
17. Retsky KL, Frei B. Vitamin C prevents metal ion-dependent initiation and propagation of lipid peroxidation in human low density lipoprotein. Biochim Biophys Acta.. 1996;1257:279-287.
18. Lynch SM, Gaziano JM, Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. In: Harris JR, ed. Ascorbic Acid: Biochemistry and Biomedical Cell Biology. New York, NY: Plenum Press; 1996:331-367.
19. Navab M, Imes SS, Hama SY, Hough GP, Ross, LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest.. 1991;88:2039-2046.
20.
Reaven PD, Ferguson E, Navab M, Powell FL.
Susceptibility of human LDL to oxidative modification: effects
of variations in ß-carotene concentration and oxygen tension.
Arterioscler Thromb.. 1994;14:1162-1169.
21. Parthasarathy S. Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein; use of a new water-soluble probucol derivative. J Clin Invest.. 1992;89:1618-1621.
22.
Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko
PW, Dhariwal KR, Park JB, Lazarev A, Graumilch JF, King J, Cantilena
LR. Vitamin C pharmacokinetics in healthy volunteers: evidence
for a recommended dietary allowance. Proc Natl Acad Sci
U S A.. 1996;93:3704-3709.
23. Dabbagh AJ, Frei B. Human suction blister interstitial fluid prevents metal ion-dependent oxidation of low density lipoprotein by macrophages and in cell-free systems. J Clin Invest.. 1995;96:1958-1966.
24. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient ultracentrifugation. Methods Enzymol.. 1986;128:181-209.[Medline] [Order article via Infotrieve]
25. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem.. 1977;83:346-356.[Medline] [Order article via Infotrieve]
26. Lynch SM, Frei B. Mechanisms of copper- and iron-dependent oxidative modification of human low density lipoprotein. J Lipid Res.. 1993;34:1745-1753.[Abstract]
27.
Stocker R, Bowry VW, Frei B. Ubiquinol-10
protects human low density lipoprotein more efficiently against lipid
peroxidation than does alpha-tocopherol. Proc
Natl Acad Sci U S A.. 1991;88:1646-1650.
28. Carter WO, Narayanan PK, Robinson JP. Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leukoc Biol.. 1994;55:253-258.[Abstract]
29. Kuzuya M, Naito M, Funaki C, Hayashi T, Asai K, Kuzuya F. Lipid peroxide and transition metals are required for the toxicity of oxidized low density lipoprotein to cultured endothelial cells. Biochim Biophys Acta.. 1991;1096:155-161.[Medline] [Order article via Infotrieve]
30. Jessup W, Simpson JA, Dean RT. Does superoxide radical have a role in macrophage-mediated oxidative modification of LDL? Atherosclerosis.. 1993;99:107-120.[Medline] [Order article via Infotrieve]
31. Ek A, Strom K, Cotgreave IA. The uptake of ascorbic acid into human umbilical vein endothelial cells and its effect on oxidant insult. Biochem Pharmacol.. 1995;50:1339-1346.[Medline] [Order article via Infotrieve]
32.
Steinbrecher UP, Witztum JL, Parthasarathy S, Steinberg
D. Decrease in reactive amino groups during oxidation or
endothelial cell modification of LDL: correlation with
changes in receptor-mediated catabolism.
Arteriosclerosis.. 1987;7:135-143.
33.
Buonassisi V, Venter JC. Hormone and
neurotransmitter receptors in an established vascular
endothelial cell line. Proc Natl Acad Sci
U S A.. 1976;73:1612-1616.
34.
Morel DW, DiCorleto PE, Chisolm GM.
Endothelial and smooth muscle cells alter low
density lipoprotein in vitro by free radical oxidation.
Arteriosclerosis.. 1984;4:357-364.
35. Bhadra S, Arshad MA, Rymaszewski Z, Norman E, Wherley R, Subbiah MT. Oxidation of cholesterol moiety of low density lipoprotein in the presence of human endothelial cells or Cu2+ ions: identification of major products and their effects. Biochem Biophys Res Commun.. 1991;176:431-440.[Medline] [Order article via Infotrieve]
36. van Hinsbergh VW, Scheffer M, Havekes L, Kempen HJ. Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim Biophys Acta.. 1986;878:49-64.[Medline] [Order article via Infotrieve]
37. Frei B, Gaziano JM. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation. J Lipid Res.. 1993;34:2135-2145.[Abstract]
38. Jialal I, Grundy SM. Preservation of the endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification. J Clin Invest.. 1991;87:597-601.
39.
Suarna C, Dean RT, May J, Stocker R. Human
atherosclerotic plaque contains both oxidized lipids and relatively
large amounts of
-tocopherol and ascorbate.
Arterioscler Thromb Vasc Biol.. 1995;15:1616-1624.
40.
Shinar E, Navok T, Chevion M. The analogous
mechanisms of enzymatic inactivation induced by ascorbate and
superoxide in the presence of copper. J Biol
Chem.. 1983;258:14778-14783.
41. Samuni A, Aronovitch J, Godinger D, Chevion M, Czapski G. On the cytotoxicity of vitamin C and metal ions: a site-specific Fenton mechanism. Eur J Biochem.. 1983;137:119-124.[Medline] [Order article via Infotrieve]
42. Miller DM, Aust SD. Studies of ascorbate-dependent, iron-catalyzed lipid peroxidation. Arch Biochem Biophys.. 1989;27:113-119.
43.
Minotti G, Aust SD. The requirement for
iron(III) in the initiation of lipid peroxidation by iron(II) and
hydrogen peroxide. J Biol Chem.. 1987;262:1098-1104.
44.
Washko P, Rotrosen D, Levine M. Ascorbic acid
transport and accumulation in human neutrophils. J
Biol Chem.. 1989;264:18996-19002.
45.
Bergsten P, Amitai G, Kehrl J, Dhariwal KR, Klein HG,
Levine M. Millimolar concentrations of ascorbic acid in purified
human mononuclear leukocytes: depletion and reaccumulation.
J Biol Chem.. 1990;265:2584-2587.
This article has been cited by other articles:
![]() |
S. Rohrbach, A. Martin, B. Niemann, and A. Cherubini Enhanced myocardial vitamin C accumulation in left ventricular hypertrophy in rats is not attenuated with transition to heart failure Eur J Heart Fail, March 1, 2008; 10(3): 226 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li and H. E. Schellhorn New Developments and Novel Therapeutic Perspectives for Vitamin C J. Nutr., October 1, 2007; 137(10): 2171 - 2184. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Montecinos, P. Guzman, V. Barra, M. Villagran, C. Munoz-Montesino, K. Sotomayor, E. Escobar, A. Godoy, L. Mardones, P. Sotomayor, et al. Vitamin C Is an Essential Antioxidant That Enhances Survival of Oxidatively Stressed Human Vascular Endothelial Cells in the Presence of a Vast Molar Excess of Glutathione J. Biol. Chem., May 25, 2007; 282(21): 15506 - 15515. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miner Fitness, Antioxidants, and Moderate Drinking: All to Lower Cardiovascular Risk American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 110 - 112. [Abstract] [PDF] |
||||
![]() |
R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sanchez-Moreno, S. E. Dorfman, A. H. Lichtenstein, and A. Martin Dietary Fat Type Affects Vitamins C and E and Biomarkers of Oxidative Status in Peripheral and Brain Tissues of Golden Syrian Hamsters J. Nutr., March 1, 2004; 134(3): 655 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sanchez-Moreno, J. F. Dashe, T. Scott, D. Thaler, M. F. Folstein, and A. Martin Decreased Levels of Plasma Vitamin C and Increased Concentrations of Inflammatory and Oxidative Stress Markers After Stroke Stroke, January 1, 2004; 35(1): 163 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Beckman, A. B. Goldfine, M. B. Gordon, L. A. Garrett, J. F. Keaney Jr., and M. A. Creager Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2392 - H2398. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sanchez-Moreno, M P. Cano, B. de Ancos, L. Plaza, B. Olmedilla, F. Granado, and A. Martin Effect of orange juice intake on vitamin C concentrations and biomarkers of antioxidant status in humans Am. J. Clinical Nutrition, September 1, 2003; 78(3): 454 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sanchez-Moreno, M. P. Cano, B. de Ancos, L. Plaza, B. Olmedilla, F. Granado, and A. Martin High-Pressurized Orange Juice Consumption Affects Plasma Vitamin C, Antioxidative Status and Inflammatory Markers in Healthy Humans J. Nutr., July 1, 2003; 133(7): 2204 - 2209. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Auger, B. Caporiccio, N. Landrault, P. L. Teissedre, C. Laurent, G. Cros, P. Besancon, and J.-M. Rouanet Red Wine Phenolic Compounds Reduce Plasma Lipids and Apolipoprotein B and Prevent Early Aortic Atherosclerosis in Hypercholesterolemic Golden Syrian Hamsters (Mesocricetus auratus) J. Nutr., June 1, 2002; 132(6): 1207 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Libby and M. Aikawa Vitamin C, Collagen, and Cracks in the Plaque Circulation, March 26, 2002; 105(12): 1396 - 1398. [Full Text] [PDF] |
||||
![]() |
G. Cao and R. L. Prior Postprandial increases in serum antioxidant capacity in older women J Appl Physiol, September 1, 2000; 89(3): 877 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Carr, B.-Z. Zhu, and B. Frei Potential Antiatherogenic Mechanisms of Ascorbate (Vitamin C) and {alpha}-Tocopherol (Vitamin E) Circ. Res., September 1, 2000; 87(5): 349 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Sherman, J. F. Keaney Jr, E. S. Biegelsen, S. J. Duffy, J. D. Coffman, and J. A. Vita Pharmacological Concentrations of Ascorbic Acid Are Required for the Beneficial Effect on Endothelial Vasomotor Function in Hypertension Hypertension, April 1, 2000; 35(4): 936 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Martin, R. Prior, B. Shukitt-Hale, G. Cao, and J. A. Joseph Effect of Fruits, Vegetables, or Vitamin E-Rich Diet on Vitamins E and C Distribution in Peripheral and Brain Tissues: Implications for Brain Function J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2000; 55(3): 144B - 151. [Abstract] [Full Text] |
||||
![]() |
B. Frei On the Role of Vitamin C and Other Antioxidants in Atherogenesis and Vascular Dysfunction Experimental Biology and Medicine, December 1, 1999; 222(3): 196 - 204. [Abstract] [Full Text] |
||||
![]() |
A. C. Chan, C. K. Chow, and D. Chiu Interaction of Antioxidants and Their Implication in Genetic Anemia Experimental Biology and Medicine, December 1, 1999; 222(3): 274 - 282. [Abstract] [Full Text] |
||||
![]() |
A. J. Dabbagh, G. T. Shwaery, J. F. Keaney Jr, and B. Frei Effect of Iron Overload and Iron Deficiency on Atherosclerosis in the Hypercholesterolemic Rabbit Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2638 - 2645. [Abstract] [Full Text] |
||||
![]() |
A. Huang, J. A. Vita, R. C. Venema, and J. F. Keaney Jr. Ascorbic Acid Enhances Endothelial Nitric-oxide Synthase Activity by Increasing Intracellular Tetrahydrobiopterin J. Biol. Chem., June 2, 2000; 275(23): 17399 - 17406. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakata and N. Maeda Vulnerable Atherosclerotic Plaque Morphology in Apolipoprotein E-Deficient Mice Unable to Make Ascorbic Acid Circulation, March 26, 2002; 105(12): 1485 - 1490. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |